Cytodyn Inc (CYDY)

[Borel Fields]

Another approach is to look at recent big pharma acquisitions. Gilead just spent $4.9b on a company called Forty Seven this March:

"The main draw for Gilead with the acquisition is Forty Seven's lead pipeline candidate magrolimab. In December 2019, Forty Seven announced encouraging results from a phase 1b clinical study evaluating the drug in combination with Vidaza in treating patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Magrolimab is also being studied as a potential treatment for diffuse large B-cell lymphoma (DLBCL)"

I don't know these diseases and markets but my naive reaction is that leronlimab is easily 5 times more valuable given the data, applications and clinical progress it has shown.